Ponesimod inhibits astrocyte‐mediated neuroinflammation and protects against cingulum demyelination via S1P(1)‐selective modulation

Ponesimod is a sphingosine 1‐phosphate (S1P) receptor (S1PR) modulator that was recently approved for treating relapsing forms of multiple sclerosis (MS). Three other FDA‐approved S1PR modulators for MS—fingolimod, siponimod, and ozanimod—share peripheral immunological effects via common S1P(1) inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Kihara, Yasuyuki, Jonnalagadda, Deepa, Zhu, Yunjiao, Ray, Manisha, Ngo, Tony, Palmer, Carter, Rivera, Richard, Chun, Jerold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740777/
https://www.ncbi.nlm.nih.gov/pubmed/34986275
http://dx.doi.org/10.1096/fj.202101531R

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740777/
https://www.ncbi.nlm.nih.gov/pubmed/34986275
http://dx.doi.org/10.1096/fj.202101531R

Ejemplares similares